Hailshadow Syros Pharmaceuticals ( NASDAQ: SYRS ) stock plunged 92% in post-market trading Tuesday after the company said a Phase 3 study of its drug tamibarotene did not meet its primary endpoint, which constituted a default event under its loan agreement with Oxford Financial. The.
Back to Health Page
